Aradigm Corporation

Type: Public
On the web: http://www.aradigm.com
Employees: 11
Employee growth: (8.3%)

Aradigm helps the medicine go down for people who swoon at the sight of a needle. Aradigm develops orally inhaled drug delivery systems that treat respiratory diseases. Its lead delivery technology, AERx (an aerosol created from liquid drug formulations), is being adapted to deliver a variety of drugs to treat pulmonary diseases. Aradigm has focused its efforts on developing respiratory treatments for conditions such as cystic fibrosis, bronchiectasis, inhaled anthrax, smoking cessation, and asthma. Aradigm typically elects to reformulate already-approved drugs (such as antibiotic ciprofloxacin) and combine them with its inhalation delivery technologies in order to speed up the regulatory process.

Key numbers for fiscal year ending December, 2011:
Sales: $0.8M
One year growth: (82.0%)
Net income: ($9.3)M

Officers:
Chairman: Virgil D. Thompson
President, CEO, and Director: Igor Gonda
VP Finance and CFO: Nancy E. Pecota

Competitors:
Alexza
Bayer HealthCare
Novartis